These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 36189255)

  • 61. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification and validation of prognostic and tumor microenvironment characteristics of necroptosis index and BIRC3 in clear cell renal cell carcinoma.
    Wei K; Zhang X; Yang D
    PeerJ; 2023; 11():e16643. PubMed ID: 38130918
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature.
    Chen W; Lin W; Wu L; Xu A; Liu C; Huang P
    Int J Med Sci; 2022; 19(2):377-392. PubMed ID: 35165523
    [No Abstract]   [Full Text] [Related]  

  • 64. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
    Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
    Front Immunol; 2022; 13():982033. PubMed ID: 36052073
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma.
    Zhang X; Zhang M; Song L; Wang S; Wei X; Shao W; Song N
    Sci Rep; 2023 Nov; 13(1):20266. PubMed ID: 37985807
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
    Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
    BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification of an independent immune-genes prognostic index for renal cell carcinoma.
    Li G; Wei X; Su S; Wang S; Wang W; Wang Y; Meng X; Xia J; Song N; Qin C
    BMC Cancer; 2021 Jun; 21(1):746. PubMed ID: 34187413
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
    Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
    BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma.
    Gu J; Zhang X; Peng Z; Peng Z; Liao Z
    Sci Rep; 2023 Nov; 13(1):18922. PubMed ID: 37919459
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment.
    Ye Y; Zeng S; Hu X
    Apoptosis; 2024 Jun; 29(5-6):693-708. PubMed ID: 38296888
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of a risk model for prognostic and therapeutic prediction in renal cell carcinoma based on infiltrating M0 cells.
    Xin S; Su J; Li R; Cao Q; Wang H; Wei Z; Wang C; Zhang C
    Sci Rep; 2024 Jun; 14(1):13390. PubMed ID: 38862642
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.
    Liu K; Huang Y; Xu Y; Wang G; Cai S; Zhang X; Shi T
    Cancer Immunol Immunother; 2023 Aug; 72(8):2557-2572. PubMed ID: 37046008
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of Treg-related prognostic molecular subtypes and individualized characteristics in clear cell renal cell carcinoma through single-cell transcriptomes and bulk RNA sequencing.
    Weng KQ; Liu JY; Li H; She LL; Qiu JL; Qi H; Qi HY; Li YS; Dai YB
    Int Immunopharmacol; 2024 Mar; 130():111746. PubMed ID: 38442575
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma.
    Li K; Li Y; Lyu Y; Tan L; Zheng X; Jiang H; Wen H; Feng C
    Front Immunol; 2022; 13():853088. PubMed ID: 35651604
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Subtype Classification and Prognosis Signature Construction of Osteosarcoma Based on Cellular Senescence-Related Genes.
    Wang H; Liu H; Wang L; Xu S; Pi H; Cheng Z
    J Oncol; 2022; 2022():4421952. PubMed ID: 36106335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.